Affordable Access

deepdyve-link
Publisher Website

New therapeutic directions for advanced pancreatic cancer: cell cycle inhibitors, stromal modifiers and conjugated therapies.

Authors
  • Matera, Robert1
  • Saif, Muhammad Wasif1
  • 1 a Department of Hematology and Oncology , Tufts University School of Medicine , Boston , MA , USA.
Type
Published Article
Journal
Expert opinion on emerging drugs
Publication Date
Sep 01, 2017
Volume
22
Issue
3
Pages
223–233
Identifiers
DOI: 10.1080/14728214.2017.1362388
PMID: 28783977
Source
Medline
Keywords
License
Unknown

Abstract

Pancreatic adenocarcinoma is a devastating malignancy with an extremely poor prognosis. These tumors progress rapidly and somewhat silently with few specific symptoms and are relatively resistant to chemotherapeutic agents. Many agents, including cell cycle inhibitors, are under development for the treatment of this cancer for which there are disappointingly few treatment options. Areas covered: Here we outline the existing approved treatments for advanced pancreatic disease and discuss a range of novel therapies currently under development including cell cycle inhibitors, stromal modifiers and conjugated therapies. We also describe the current state of the pancreatic cancer therapeutics market both past and future. Expert opinion: Despite the recent explosion of novel therapies with an array of unique targets, the core treatment of pancreatic cancer still with traditional cytotoxic agents with a few exceptions. However, as these novel treatments move through the pipeline, we are hopeful that there will soon be a number of effective options for patients with advanced pancreatic cancer.

Report this publication

Statistics

Seen <100 times